Showing 20 of 75 recruiting trials for “squamous-cell-carcinoma-of-the-larynx”
Enrolling by InvitationNCT06763640 ↗
Prognostic Value of TIL in Nasopharyngeal Carcinoma
CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
👨⚕️ Bo You, Doctor, Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Nantong University📍 1 site📅 Started Aug 2024View details ↗
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
👨⚕️ Melvin LK CHUA, MBBS, FRCR, PhD, FAMS, National Cancer Centre, Singapore📍 2 sites📅 Started Jul 2024View details ↗
RecruitingNCT06463392 ↗
Deep Learning-based sbORN Diagnostic Model
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
RecruitingNCT06445088 ↗
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
👨⚕️ Jingao Li, MD, NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital📍 1 site📅 Started Feb 2024View details ↗
RecruitingNCT06307314 ↗
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
👨⚕️ Jian Guan, Ph.D., Nanfang Hospital, Southern Medical University📍 5 sites📅 Started Feb 2024View details ↗
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →